Methods for determining the origin of dna molecules

Patent metadata

Field	Value
Publication number	US-2018327825-A1
Application number	US-201615773789-A
Country	US
Kind code	A1
Filing date	Nov 9, 2016
Priority date	Nov 9, 2015
Publication date	Nov 15, 2018
Grant date	—

Abstract

The invention provides methods and nucleic acid molecules for determining the presence of DNA molecules from an origin of interest in a subject.

First claim

We claim:

1 . A method for determining the presence of DNA molecules from an origin of interest in a population of DNA molecules present in a cell-free bodily fluid sample from a subject, said method comprising:
a) obtaining a DNA sample isolated from a cell-free bodily fluid sample from the subject; b) determining a plurality of protein binding site sequences and their 5′ and 3′ flanking region sequences for each of one or more proteins, wherein at least one of the one or more proteins differentially binds to DNA molecules of differing origin; c) aligning at least a plurality of the determined protein binding site sequences for each of the one or more proteins; d) counting the number of sequencing reads starting at each nucleotide position within each 5′ and 3′ flanking region sequence of the aligned protein binding site sequences; e) generating a coverage map based on the number of counts of step d); f) filtering the coverage map to identify at least one periodic component within the coverage map; g) obtaining a metric that is representative of a strength of the at least one periodic component within the coverage map; wherein the computed metric is indicative of the presence of DNA molecules from the origin of interest.

2 . The method of claim 1 , wherein the bodily fluid sample is a blood sample.

3 . The method of claim 2 , wherein the blood sample is from a pregnant woman.

4 . The method of any one of claims 1 - 3 , wherein the DNA molecules of differing origin are DNA molecules of maternal origin and DNA molecules of fetal origin.

5 . The method of claim 4 , wherein the computed metric is indicative of fetal DNA fraction.

6 . The method of claim 1 , wherein the DNA molecules of differing origin are DNA molecules of diseased cells and DNA molecules of non-diseased cells.

7 . The method of claim 1 , wherein the DNA molecules of differing origin are DNA molecules of a first tissue origin and DNA molecules of a second tissue origin.

8 . The method of claim 1 , wherein the DNA molecules of differing origin are DNA molecules of a first tissue origin and DNA molecules of leukocyte origin.

9 . The method of any one of claims 1 - 8 , wherein the determining is performed by sequencing.

10 . The method of claim 9 , wherein the sequencing is massively parallel sequencing.

11 . The method of claim 9 , wherein the sequencing is targeted sequencing.

12 . The method of any one of claims 1 - 11 , wherein the proteins are transcription factors and the protein binding site sequences are transcription factor binding site sequences.

13 . The method of any one of claims 1 - 11 , wherein the proteins are nucleases and the protein binding site sequences are nuclease binding sequences.

14 . The method of any one of claims 1 - 13 , wherein the aligning is an alignment against a genomic reference sequence.

15 . The method of any one of claims 1 - 14 , wherein the plurality of protein binding site sequences comprises at least 500, at least 1,000, at least 1,500, at least 2,000, at least 3,000, at least 4,000, at least 5,000, at least 10,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 60,000, at least 70,000, at least 80,000, at least 90,000, at least 100,000, at least 110,000, at least 120,000, at least 130,000, at least 140,000, at least 150,000, at least 160,000, at least 170,000, at least 180,000, at least 190,000, at least 200,000, at least 210,000, at least 220,000, at least 230,000, at least 240,000, at least 250,000, at least 260,000, at least 270,000, at least 280,000, at least 290,000, at least 300,000, at least 310,000, at least 320,000, at least 330,000, at least 340,000, at least 350,000, at least 360,000, at least 370,000, at least 380,000, at least 390,000, at least 400,000, at least 410,000, at least 420,000, at least 430,000, at least 440,000, at least 450,000, at least 460,000, at least 470,000, at least 480,000, at least 490,000, or at least 500,000 protein binding site sequences.

16 . The method of any one of claims 1 - 15 , wherein the one or more proteins is two proteins.

17 . The method of any one of claims 1 - 15 , wherein the one or more proteins is three proteins.

18 . The method of any one of claims 1 - 15 , wherein the one or more proteins is four proteins.

19 . The method of any one of claims 1 - 15 , wherein the one or more proteins is five proteins.

20 . The method of any one of claims 1 - 15 , wherein the one or more proteins is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 or more proteins.

21 . The method of any one of claims 1 - 20 , wherein the 5′ and 3′ flanking region sequences are at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1,000, at least 1,100, at least 1,200, at least 1,300, at least 1,400, at least 1,500, or at least 2,000 base pairs.

22 . The method of any one of claims 1 - 21 , wherein the filtering of step f) comprises computing a spectral frequency transform of the coverage map and identifying a power of the spectral frequency transform within a frequency band.

23 . The method of claim 22 , wherein the frequency band includes frequencies corresponding to spacings of 130 to 250 base pairs.

24 . The method of any one of claim 22 or 23 , wherein the metric is a ratio between the power of the spectral frequency transform within a frequency band and an overall power of the spectral frequency transform.

25 . The method of claim 24 , wherein the power of the spectral frequency transform is computed by integrating the spectral frequency transform within the frequency band, and the overall power of the spectral frequency transform is computed by integrating the spectral frequency transform over all frequencies.

26 . The method of any one of claims 1 - 25 , wherein the at least one periodic component is indicative of aligned positions across nucleosomes, such that a local maximum in the at least one periodic component is indicative of an absence of nucleosomes at the corresponding nucleotide position, and a local minimum in the at least one periodic component is indicative of a presence of nucleosomes at the corresponding nucleotide position.

27 . The method of any one of claims 1 - 26 , wherein the metric is a signal-to-noise ratio that is computed from the filtered coverage map.

28 . The method of any one of claims 1 - 27 , further comprising determining a proportion of DNA molecules from two or more origins of interest.

29 . The method of claim 28 , wherein the two or more origins of interest are tissues.

Assignees

• Progenity Inc

Inventors

• Mann Tobias

Classifications

• C12Q1/6848 Primary

  characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q2535/122

  Massive parallel sequencing · CPC title

• C12Q2537/165

  Mathematical modelling, e.g. logarithm, ratio · CPC title

• C12Q1/6858

  Allele-specific amplification · CPC title